
Edmond de Rothschild Investment Partners sells Covagen to Cilag
Edmond De Rothschild Investment Partners’s (EdRIP) BioDiscovery 3 portfolio company, Covagen AG, has been acquired by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Company. Covagen is a privately-held, biopharmaceutical company specialising in the development of multi-specific protein therapeutics through the FynomAb technology platform. The company's lead product, COVA322,